- Home
- ESRT vs BEAM Comparison
ESRT vs BEAM Comparison
Compare ESRT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESRT
- BEAM
- Stock Information
- Founded
- ESRT 2011
- BEAM 2017
- Country
- ESRT United States
- BEAM United States
- Employees
- ESRT N/A
- BEAM N/A
- Industry
- ESRT Real Estate Investment Trusts
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESRT Real Estate
- BEAM Health Care
- Exchange
- ESRT Nasdaq
- BEAM Nasdaq
- Market Cap
- ESRT 1.8B
- BEAM 1.9B
- IPO Year
- ESRT 2013
- BEAM 2020
- Fundamental
- Price
- ESRT $10.60
- BEAM $24.05
- Analyst Decision
- ESRT Hold
- BEAM Buy
- Analyst Count
- ESRT 3
- BEAM 11
- Target Price
- ESRT $10.67
- BEAM $45.90
- AVG Volume (30 Days)
- ESRT 1.2M
- BEAM 1.3M
- Earning Date
- ESRT 10-21-2024
- BEAM 11-05-2024
- Dividend Yield
- ESRT 1.32%
- BEAM N/A
- EPS Growth
- ESRT N/A
- BEAM N/A
- EPS
- ESRT 0.27
- BEAM N/A
- Revenue
- ESRT $763,203,000.00
- BEAM $349,643,000.00
- Revenue This Year
- ESRT N/A
- BEAM N/A
- Revenue Next Year
- ESRT $2.20
- BEAM $6.04
- P/E Ratio
- ESRT $38.80
- BEAM N/A
- Revenue Growth
- ESRT 4.84
- BEAM 328.73
- 52 Week Low
- ESRT $8.39
- BEAM $20.84
- 52 Week High
- ESRT $11.62
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- ESRT 41.98
- BEAM 46.67
- Support Level
- ESRT $10.76
- BEAM $21.46
- Resistance Level
- ESRT $11.01
- BEAM $32.29
- Average True Range (ATR)
- ESRT 0.24
- BEAM 2.04
- MACD
- ESRT -0.03
- BEAM 0.19
- Stochastic Oscillator
- ESRT 19.14
- BEAM 23.92
About ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.